(Q35741937)

10 August 2017

1 reference

title

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies (English)

1 reference

10 August 2017

2

Srdan Verstovsek

1 reference

10 August 2017

3

Francis Giles

1 reference

10 August 2017

Amit Panwalkar

1

1 reference

PubMed ID

15073843

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

10 August 2017

1 reference

10 August 2017

100

1 reference

10 August 2017

8

1 reference

10 August 2017

1578-1589

1 reference

CD40 ligand in CLL pathogenesis and therapy

10 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Function and activation of NF-kappa B in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Function of NF-kappa B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Characterization of a novel promoter insertion in the c-rel locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Functional interaction of the v-Rel and c-Rel oncoproteins with the TATA-binding protein and association with transcription factor IIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

Deregulation of NF-kappaB and its upstream kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Transducing signals from antigen receptors to nuclear factor kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Hodgkin's lymphoma and CD30 signal transduction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Nuclear factor-kappa B, cancer, and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappa B: arresting a major culprit in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Multiple nuclear factors interact with the immunoglobulin enhancer sequences

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Phylogenetic perspectives in innate immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

ATP-dependent proteases degrade their substrates by processively unraveling them from the degradation signal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappa B: ten years after

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Aberrant rel/nfkb genes and activity in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappaB and virus infection: who controls whom

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Identification and characterization of an IkappaB kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

IKAP is a scaffold protein of the IkappaB kinase complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Direct Phosphorylation of IB by IKK and IKK: Discrimination Between Free and NF-B-Bound Substrate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappaB signaling pathways in mammalian and insect innate immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The IKK complex: an integrator of all signals that activate NF-kappaB?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The carboxyl-terminal region of IkappaB kinase gamma (IKKgamma) is required for full IKK activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Proteasome inhibitors: from research tools to drug candidates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Duration of nuclear NF-kappaB action regulated by reversible acetylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

NF-kappaB and cell-cycle regulation: the cyclin connection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Inhibitors of mammalian G1 cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The retinoblastoma protein and cell cycle control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Bcl-3-mediated nuclear regulation of the NF-kappa B trans-activating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NFKB2) and the I kappa B/MAD-3 (NFKBI) inhibitor of NF-kappa B to 4q24 and 14q13, respectively

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Phenotypic and genotypic characterization of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Hodgkin's disease: a tumor with disturbed immunological pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Nuclear transcription factor-kappaB in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The role of Epstein-Barr virus in neoplastic transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Downstream effectors of oncogenic ras in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

The IKK NF-kappa B system: a treasure trove for drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Novel IKK inhibitors: beta-carbolines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20182

7 January 2021

Identifiers

DOI

10.1002/CNCR.20182

1 reference

10 August 2017

1 reference

PubMed ID

15073843